Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation

被引:8
|
作者
Vrachimis, A. [1 ]
Schober, O. [1 ]
Riemann, B. [1 ]
机构
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2012年 / 51卷 / 03期
关键词
Radioiodine; remnant ablation; thyroid hormone withdrawal; rhTSH; RECOMBINANT HUMAN THYROTROPIN; HORMONE WITHDRAWAL; FOLLOW-UP; CARCINOMA; THERAPY; HYPOTHYROIDISM; RISK; MANAGEMENT; RHTSH; COST;
D O I
10.3413/Nukmed-0432-11-10
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: Radioiodine remnant ablation (RRA) after (near-)total thyroidectomy (TE) is a key element in patients with differentiated thyroid cancer (DTC). The use of exogenous TSH stimulation (rhTSH) prior to RRA has shown promising results as compared to conventional thyroid hormone withdrawal (THW). As yet, the efficacy of RRA after brief THW and single rhTSH administration has not been assessed. Patients, methods: The study sample comprised 147 patients with DTC referred to our center between May 2008 and September 2010. All patients received TE with subsequent RRA. None of these 147 patients had evidence of distant metastasis. 93 patients had endogenous TSH stimulation 4-5 weeks after surgery (group I) and twenty-six received two rhTSH injections (group II). 28 patients were treated with a single rhTSH injection after a brief THW (group III). RRA-Efficacy was assessed three months after therapy by diagnostic whole-body scan and measurement of the tumour marker thyroglobulin (Tg) under TSH stimulation. Results: Three categories of success were defined for remnant ablation. Based on the definition of successful remnant ablation no visible uptake and a Tg <= 2.0 ng/ml (category 1) was seen in 62/93 patients in group I, in 17/26 patients in group II (p = n.s.) and in 12/28 patients in group III (p < 0.05). Visible radioiodine uptake and a Tg <= 2.0 ng/ml (category 2) was seen in 16/28 patients of group III and thus significantly more frequent than in group I (28/93 patients) (p < 0.01). However, patients in group III (16/28 patients) and group II (8/26 patients) showed no significant difference in this category (p = n.s.). Visible radioiodine uptake and a Tg > 2.0 ng/ml (category 3) was found in 3/93 patients in group I and 1/26 patients in group II but in no patient in group III. Conclusion:The third strategy of remnant ablation using a single injection of rhTSH after a brief THW period resulted in a significant higher rate of patients with residual uptake in the thyroid bed and a Tg level below 2 ng/ml three months after remnant ablation in comparison to THW. However, the overall efficacy of the third protocol was not significantly different as compared to two rhTSH injections. Under the aspect of the supply shortage of rhTSH the combined endogenous and exogenous TSH stimulation may be an attractive alternative for remnant ablation in differentiated thyroid cancer.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [21] The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy
    Fu, Hongliang
    Ma, Chao
    Li, Jianing
    Feng, Fang
    Wu, Shuqi
    Ye, Zhiyi
    Wang, Hui
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 60 (03): : 280 - 284
  • [22] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Frederik A. Verburg
    Markus Dietlein
    Michael Lassmann
    Markus Luster
    Christoph Reiners
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [23] Editorial: Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation
    Haugen, BR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (08): : 3665 - 3667
  • [24] Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma
    Verburg, Frederik A.
    Dietlein, Markus
    Lassmann, Michael
    Luster, Markus
    Reiners, Christoph
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (03) : 343 - 346
  • [25] Analysis of Critical Parameters for Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Carcinoma
    Mika, A. Valkovic
    Nekic, J.
    Ivankovic, S. Grbac
    Valkovic, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S482 - S482
  • [26] PROTOCOL FOR THYROID REMNANT ABLATION AFTER RECOMBINANT TSH IN THYROID CARCINOMA
    Pitoia, Fabian
    El Tamer, Elias
    Eugenia Salvai, Maria
    Niepomniszcze, Hugo
    MEDICINA-BUENOS AIRES, 2009, 69 (02) : 148 - 152
  • [27] Radioiodine Ablation Rate of Well Differentiated Thyroid Cancer Patients with Un-Elevated TSH levels
    Yilmaz, S.
    Kabasakal, L.
    Onsel, C.
    Sayman, H. B.
    Kanmaz, B.
    Sonmezoglu, K.
    Uslu, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S240 - S240
  • [28] Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer
    Pacini, Furio
    EUROPEAN THYROID JOURNAL, 2016, 5 (01) : 7 - +
  • [29] A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Robbins, RJ
    Larson, SM
    Sinha, N
    Shaha, A
    Divgi, C
    Pentlow, KS
    Ghossein, R
    Tuttle, RM
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (11) : 1482 - 1488
  • [30] Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma
    Jinguji, M.
    Nakajo, M.
    Tani, A.
    Yoshiura, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S783 - S784